Cancer
APOLLO
Pancreatic Cancer
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Contact Research Team:
[email protected]
Site principal investigator:
Marc Roth, MD
Learn more about this study:
NCT04858334